scholarly journals Radionuclide study in gastroparesis: Is it still relevant?

2016 ◽  
Vol 15 (1) ◽  
Author(s):  
Mohamad Shahrir Abdul Rahim ◽  
Ibrahim Lutfi bin Shuaib ◽  
Sazilah binti Ahmad Sarji
Keyword(s):  
Quality Of Life ◽  
Clinical Symptoms ◽  
Gastrointestinal Symptoms ◽  
Mechanical Obstruction ◽  
Radionuclide Scintigraphy ◽  
Radionuclide Study ◽  
Approaches To Study ◽  
High Index Of Suspicion

The incidence of gastroparesis in Malaysia is not well documented. Gastroparesis may present with various combinations of debilitating sign and symptoms that decrease quality of life and increases morbidity. It is diagnosed based on clinical symptoms and exclusion of the obstruction. There should be a high index of suspicion in patients who present with symptoms to avoid missing the diagnosis. There are various approaches to study the gastric motility. Here’s a case of a young adult woman with type 1 diabetes mellitus suffering severe gastrointestinal symptoms. In this case, radionuclide scintigraphy is used as one of the investigation to confirm the diagnosis of gastroparesis. Radionuclide scintigraphy remains a hallmark in the diagnosis of gastroparesis after excluding mechanical obstruction.

scholarly journals Effectiveness of mebeverine in patients with post-cholecystectomy gastrointestinal spasm: results of prospective observational program “odyssey”

2018 ◽  
Vol 90 (8) ◽  
pp. 40-47 ◽  
Author(s):  
I V Maev ◽  
Yu A Kucheravy ◽  
V V Tsukanov ◽  
E Yu Eremnia ◽  
D N Andreev ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Abdominal Pain ◽  
Surgical Treatment ◽  
Rating Scale ◽  
Clinical Symptoms ◽  
Gastrointestinal Symptoms ◽  
Marked Change ◽  
Numeric Rating Scale ◽  
Observational Assessment

Aim: to assess the effectiveness of mebeverine 200 mg BID in patients with post-cholecystectomy gastrointestinal spasm not requiring surgical treatment. Materials and methods. 218 patients were included in 16 clinical centers in 14 cities in Russia. All patients had post-cholecystectomy gastrointestinal spasms, not requiring surgical treatment and received mebeverine (Duspatalin®) 200 mg BID. The observational assessment period lasted from the moment of their inclusion into the study up to 6 weeks post inlusion. The therapy results were evaluated using visual analog scales (GPA and 11-point numeric rating scale) by patient self-assessment of the dynamics of spasm/discomfort and other post-cholecystectomic gastrointestinal symptoms after 2 and 6 weeks of treatment. Gastrointestinal Quality of Life Index (GIQLI) was used to assess patient quality of life. Results and discussion. All 218 patients completed the 2-week mebeverine treatment course, 101 of them finished the 6-week course (“prolonged population”). Significant positive changes in the relief of abdominal pain and dyspepsia were noted as well as normalization of stool frequency and consistency. A more marked change in values was observed during prolonged (up to 6 weeks) therapy. Both 2-week and 6-week mebeverine courses led to a normalization of patient quality of life. After 6 week therapy, an effect of mebeverine on the quality of life 91% of patients was observed comparable to cholecystectomy itself, speficially related to the quality of life subscore ‘symptoms’. Conclusion. The results of our study demonstrate that mebeverine (Duspatalin®) therapy leads to an effective elimination of clinical symptoms associated with post-cholecystectomy GI-spasm disorders, like abdominal pain, symptoms of dyspepsia and stooldisorders. A more marked change in values was observed during prolonged (up to 6 weeks) therapy.

Management of gastrointestinal symptoms in palliative care

2020 ◽  
Vol 13 (5) ◽  
pp. 273-279
Author(s):  
Monica Kumar
Keyword(s):  
Quality Of Life ◽  
Palliative Care ◽  
Systematic Approach ◽  
Clinical Symptoms ◽  
Gastrointestinal Symptoms ◽  
Health Needs ◽  
Team Approach ◽  
Advanced Malignancy ◽  
The Mind

The management of symptoms related to the gastrointestinal tract is an ongoing challenge in the care of patients with advanced malignancy. Clinical symptoms are often detrimental to a patient’s quality of life. The goal of palliative medicine includes care of the mind, body, and spirit. Symptom management and improving quality of life for patients and their families is paramount. As the population ages, this results in more complex health needs and the need for a multidisciplinary team approach. This article will outline a general and systematic approach to managing gastrointestinal symptoms in palliative care; it will emphasise the importance of holistic medicine in improving a patient’s quality of life.

scholarly journals Exploring associations between constipation, severity of neurofibromatosis type 1 and NF1 mutational spectrum

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Cecilie Ejerskov ◽  
Mette Gaustadnes ◽  
John R. Ostergaard ◽  
klaus Krogh ◽  
Kasper Thorsen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Neurofibromatosis Type 1 ◽  
Case Reports ◽  
Gastrointestinal Symptoms ◽  
Neurofibromatosis Type ◽  
Illness Burden ◽  
Mutational Spectrum ◽  
High Degree

AbstractNeurofibromatosis type 1 (NF1) is inherited in an autosomal dominant manner and is a rather common rare disease. Until recently, studies on gastrointestinal symptoms in patients with NF1 have been few and mostly described as case reports. In three previously published studies, the frequency of constipation in patients with NF1 has been found to be as high as 30%. In this study, associations between the frequency of constipation and NF1 disease severity and NF1 mutational spectrum were investigated. Among 277 patients with NF1, 49 had constipation. The highest rate of constipation was found among patients with a high perception of NF1 illness burden, and patients with constipation had a significantly higher NF1 illness burden when comparing the “not bothered” and the “very bothered” (p = 0.013). We found no significant association between constipation and the remaining measures on severity of NF1, nor between constipation and genetic variants. When observing the NF1 mutational spectrum, one variant (c.1013A>G (p.Asp338Gly/p.?) was identified in three patients with constipation of which two patients were related. The variant c.2970_2972delAAT (p.Met992del) associated with a mild NF1 phenotype was identified in two related patients with constipation. This study is the first to explore the association between symptoms of constipation, NF1 severity, and NF1 mutational spectrum. The results suggest an association between constipation and a high degree of illness burden. Awareness of this association among physicians could lead to more patients with NF1 being diagnosed with constipation. Constipation impacts on quality of life, hence a timely diagnosis and treatment will improve quality of life.

scholarly journals COVID-19 and influenza: main differences between clinical symptoms

2021 ◽  
Vol 2 (1) ◽  
pp. 25-32
Author(s):  
V.O. Boyko
Keyword(s):  
Quality Of Life ◽  
Differential Diagnosis ◽  
Exponential Growth ◽  
Clinical Symptoms ◽  
Clinical Course ◽  
Clinical Manifestations ◽  
Gastrointestinal Symptoms ◽  
Neurological Manifestations ◽  
Asymptomatic Carriage

This review analyzes the clinical symptoms, differential diagnosis of COVID-19 and influenza to facilitate clinical diagnosis of both diseases. The development of the COVID-19 epidemic occurred with an exponential growth of the incidence due to the high contagiousness of the virus, asymptomatic carriage. The situation was aggravated by the contagiousness of the patient in the last 2–3 days of the incubation period (before clinical manifestations), which made it difficult to isolate patients and contacts in a timely. The spectrum of damage to the organs and systems is constantly expanding with a more detailed study of the clinical course of COVID-19. Sometimes, the manifestations of COVID-19 persist even during the period of convalescence, which cause a decrease in the performance and quality of life of patients. The article discusses neurological manifestations, gastrointestinal symptoms and features of pneumonia in COVID-19. The clinical features of influenza and the main differences in the clinical course from COVID-19 are also demonstrated.

scholarly journals Lower gastrointestinal symptoms are associated with worse glycemic control and quality of life in type 1 diabetes mellitus

2018 ◽  
Vol 6 (1) ◽  
pp. e000514 ◽  
Author(s):  
John S Leeds ◽  
Marios Hadjivassiliou ◽  
Solomon Tesfaye ◽  
David S Sanders
Keyword(s):  
Quality Of Life ◽  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Short Form ◽  
Gastrointestinal Symptoms ◽  
High Yield ◽  
Bowel Habit ◽  
Life Questionnaire

ObjectivesLower gastrointestinal symptoms are not well characterized in people with type 1 diabetes, and the effects on quality of life and glycemic control are unknown. This study aimed to determine the prevalence of lower gastrointestinal symptoms and the effects on glycemic control and quality of life, and to investigate for underlying causes.Research design and methodsThis is a prospective, cohort study in secondary care. Patients with type 1 diabetes completed a gastrointestinal symptom questionnaire and the Short Form 36 V.2 quality of life questionnaire and had their hemoglobin A1c measured. Patients with diarrhea were offered reassessment and investigation as per the national guidelines. Controls without diabetes were used to compare symptom prevalence and quality of life scores.Results 706 with type 1 diabetes (mean age 41.9 years) and 604 controls (mean age 41.9 years) were enrolled. Gastrointestinal symptoms were significantly more frequent in type 1 diabetes compared with controls, in particular constipation (OR 2.4), diarrhea (OR 2.5), alternating bowel habit (OR 2.1), abdominal pain (OR 1.4), floating stools (OR 2.7), bloating (OR 1.4) and flatulence (OR 1.3) (all p<0.05). Previous pancreatitis was more frequent in type 1 diabetes (OR 4.6), but other gastrointestinal conditions were not. Gastrointestinal symptoms were associated with poorer glycemic control (p<0.01) and worse quality of life particularly in those with diarrhea. Investigation of those with diarrhea, including those with alternating bowel habit, (n=105), identified a cause in 72.3% with subsequent change in management.ConclusionsGastrointestinal symptoms are twice as common in type 1 diabetes and associated with poorer quality of life and glycemic control. Investigation of diarrhea in people with type 1 diabetes leads to a high yield of treatable conditions and a change in management in about three-quarters.

851-P: Sleep and Quality of Life in Adolescents with Type 1 or Type 2 Diabetes

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 851-P
Author(s):  
MELISSA S. FAULKNER
Keyword(s):  
Quality Of Life ◽  
Type 2 Diabetes
Sign in / Sign up

Export Citation Format

Share Document